<DOC>
	<DOCNO>NCT02944071</DOCNO>
	<brief_summary>This clinical study prospective , non-randomized , multicenter study demonstrate acceptable safety performance angioplasty Ranger DCB native femoropopliteal artery lesion . It intend patient qualify lesion would consider enrollment treat Ranger DCB catheter . Approximately 123 patient femoropopliteal artery lesion enrol . All lesion treat Ranger DCB . Up 15 clinical site locate China expect participate .</brief_summary>
	<brief_title>Clinical Study Boston Scientific Paclitaxel-Coated PTA（Percutaneous Transluminal Angioplasty） Balloon Catheter ( Ranger™ Ranger™ SL ( OTW ) DCB ) China</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects must age 18 old Subject willing able provide inform consent Subject available willing attend require followup visit Subject clinically significant symptomatic leg ischemia Subject Rutherford clinical category 2 4 If index lesion restenotic , prior PTA must &gt; 90 day prior treatment current study Only one lesion per limb treat protocol , mean one index lesion , one index limb `` treatment '' . However , limb may treat either index procedure and/or subsequent procedure Successful intraluminal wire cross target lesion Angiographic Al1.The index lesion clinically hemodynamically de novo stenotic restenotic lesion locate native nonstented superficial femoral artery proximal popliteal artery Hunter 's Canal popliteal fossa ( i.e . within P1 segment ) , follow characteristic visual assessment : Degree stenosis ≥ 70 % Target vessel diameter ≥ 2.0 mm ≤ 8.0 mm Lesion length ≥ 20 mm ≤ 200 mm , cover one two balloon ( ) ( minimal overlap ) For diffuse lesion multiple lesion target vessel , total lesion length , include distance lesion , must ≤ 200 mm AI2 . The subject least one patent infrapopliteal artery ( &lt; 50 % stenosis ) foot prior index procedure Subjects undergone prior vascular surgery SFA/PPA（Superficial Femoral Artery / Proximal Popliteal Artery） index limb treat atherosclerotic disease History major amputation limb target lesion Presence aneurysm target vessel ( ) Acute ischemia and/or acute thrombosis artery low limb Acute Myocardial Infarction within 30 day index procedure History hemorrhagic stroke within 3 month History thrombolysis angina within 2 week enrollment Persistent , intraluminal thrombus propose target lesion post thrombolytic therapy Known hypersensitivity contraindication contrast dye , opinion investigator , adequately premedicated Known allergy Paclitaxel component use medical device Intolerance antiplatelet , anticoagulant , thrombolytic medication would administer trial Platelet count &lt; 80,000 mm3 &gt; 700,000 mm3 Concomitant renal failure serum creatinine &gt; 2.0 mg/dL Receiving dialysis immunosuppressant therapy Life expectancy less one year Women childbearing potential use reliable method contraception time screen 12 month index procedure . Woman pregnant nursing . ( Pregnancy test must perform within 72 hour prior index procedure , except woman definitely childbearing potential ) . Previously plan stenting index lesion ( stent allow bailout situation like flowlimiting dissection ) Use adjunctive therapy ( debulking , laser , cryoplasty , reentry device ) Subjects major procedure ( cardiac , aorta , peripheral ) within 30 day prior index procedure Planned expect procedure ( cardiac , aorta , peripheral ) within 30 day post index procedure Presence outflow lesion require intervention within 30 day index procedure Perforated vessel evidence extravasation contrast medium Heavily calcify target lesion resistant PTA Current participation another drug device trial complete primary endpoint , include clinical study use drugcoated drugeluting technology , may potentially confound result trial , would limit subject 's compliance followup requirement Current past intervention use drugcoated/drugeluting technology index limb Target lesion instent restenosis ( stent stentgraft ) Angiographic AE1 . Subjects ipsilateral iliac inflow lesion , unsuccessful treatment prior index procedure ( i.e. , residual stenosis ≥ 30 % post treatment AE2 . Subjects patent infrapopliteal artery ( i.e. , ≥ 50 % stenosis ) foot prior index procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>femoropopliteal artery lesion</keyword>
	<keyword>Percutaneous Transluminal Angioplasty</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>Drug-coated Balloon</keyword>
</DOC>